Literature DB >> 31562849

Neurosteroids and neuropathic pain management: Basic evidence and therapeutic perspectives.

Laurence Meyer1, Omar Taleb1, Christine Patte-Mensah1, Ayikoe-Guy Mensah-Nyagan2.   

Abstract

Complex mechanisms involved in neuropathic pain that represents a major health concern make its management complicated. Because neurosteroids are bioactive steroids endogenously synthesized in the nervous system, including in pain pathways, they appear relevant to develop effective treatments against neuropathic pain. Neurosteroids act in paracrine or autocrine manner through genomic mechanisms and/or via membrane receptors of neurotransmitters that pivotally modulate pain sensation. Basic studies which uncovered a direct link between neuropathic pain symptoms and endogenous neurosteroid production/regulation, paved the way for the investigations of neurosteroid therapeutic potential against pathological pain. Concordantly, antinociceptive properties of synthetic neurosteroids were evidenced in humans and animals. Neurosteroids promote peripheral analgesia mediated by T-type calcium and gamma-aminobutyric acid type A channels, counteract chemotherapy-induced neuropathic pain and ameliorate neuropathic symptoms of injured spinal cord animals by stimulating anti-inflammatory, remyelinating and neuroprotective processes. Together, these data open interesting perspectives for neurosteroid-based strategies to manage/alleviate efficiently neuropathic pain.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic pain; Neuroactive steroid; Neuroprotection; Neurosteroid; Nociception; Peripheral neuropathy

Mesh:

Substances:

Year:  2019        PMID: 31562849     DOI: 10.1016/j.yfrne.2019.100795

Source DB:  PubMed          Journal:  Front Neuroendocrinol        ISSN: 0091-3022            Impact factor:   8.606


  8 in total

1.  Structure-Activity Relationship of Neuroactive Steroids, Midazolam, and Perampanel Toward Mitigating Tetramine-Triggered Activity in Murine Hippocampal Neuronal Networks.

Authors:  Shane Antrobus; Brandon Pressly; Atefeh Mousavi Nik; Heike Wulff; Isaac N Pessah
Journal:  Toxicol Sci       Date:  2021-04-12       Impact factor: 4.849

Review 2.  Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant.

Authors:  Rachida Guennoun
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

3.  Preemptive Analgesic Effect of Intrathecal Applications of Neuroactive Steroids in a Rodent Model of Post-Surgical Pain: Evidence for the Role of T-Type Calcium Channels.

Authors:  Quy L Tat; Srdjan M Joksimovic; Kathiresan Krishnan; Douglas F Covey; Slobodan M Todorovic; Vesna Jevtovic-Todorovic
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

Review 4.  Physiopathological Role of Neuroactive Steroids in the Peripheral Nervous System.

Authors:  Eva Falvo; Silvia Diviccaro; Roberto Cosimo Melcangi; Silvia Giatti
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

5.  Analysis of Potential Hub Genes for Neuropathic Pain Based on Differential Expression in Rat Models.

Authors:  Jie Bai; Bin Geng; Xingwen Wang; Shenghong Wang; Yayi Xia
Journal:  Pain Res Manag       Date:  2022-03-03       Impact factor: 3.037

Review 6.  A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.

Authors:  Laurent Monassier; Ayikoé Guy Mensah-Nyagan; Nicolas Collongues; Guillaume Becker; Valérie Jolivel; Estelle Ayme-Dietrich; Jérôme de Seze; Fabien Binamé; Christine Patte-Mensah
Journal:  Neurol Ther       Date:  2022-05-24

Review 7.  Allopregnanolone: An overview on its synthesis and effects.

Authors:  Silvia Diviccaro; Lucia Cioffi; Eva Falvo; Silvia Giatti; Roberto Cosimo Melcangi
Journal:  J Neuroendocrinol       Date:  2021-06-29       Impact factor: 3.870

8.  Albiflorin Attenuates Mood Disorders Under Neuropathic Pain State by Suppressing the Hippocampal NLRP3 Inflammasome Activation During Chronic Constriction Injury.

Authors:  Pei Liu; Jianjun Chen; Shuai Ma; Jianjun Zhang; Jianyu Zhou
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.